Respiro Diagnostics develops a breath-based liquid biopsy platform for early, non-invasive detection of lung cancer and other pulmonary diseases.
The company captures biological material from exhaled breath and analyzes DNA, RNA, and proteins to enable earlier, safer, and more accessible respiratory diagnostics for clinical and screening applications.
Leadership & Board
Key Executives
FounderAlison Quinn
FounderTheo Issitt
Current Number of Employees3
Current LinkedIn Followers937
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$1M
Total Amount Raised$1M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$1M
Latest Funding Amount$1M
Latest Funding RoundPre-Seed
Latest Funding RoundPre-Seed
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Respiro Diagnostics had 3 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
3Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Respiro Diagnostics had 937 followers as of September 28, 2026. The number of followers increased by 8 (0.86%) week-over-week.
937Latest Followers Count
8(0.86%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jul 14, 2026
Pre-Seed
$1.30M
―
Similar Companies
A snapshot of private companies similar to Respiro Diagnostics, helping you discover and navigate related company profiles.